Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) generates frequent news as a global eye care company listed on the SIX Swiss Exchange and the New York Stock Exchange. Company communications emphasize a long heritage in eye care, a broad Surgical and Vision Care portfolio, and a large international patient reach, which together make Alcon a regular subject of healthcare, medical device and capital markets coverage.
News about Alcon often highlights developments in its Surgical and Vision Care segments, including product launches and portfolio updates that address conditions such as cataracts, glaucoma, retinal diseases and refractive errors. The company has stated that it is advancing global launches of major products across these franchises, and such initiatives are typically announced through press releases and investor events.
Investors following ALC news can also expect updates on corporate strategy and transactions. For example, Alcon has reported on a definitive merger agreement with STAAR Surgical Company and later announced the termination of that agreement in a January 6, 2026 press release. These items appear in both company news and related regulatory filings, providing insight into how Alcon approaches acquisitions and refractive surgery strategy.
Coverage may further include Alcon’s participation in major healthcare conferences, where senior executives present the company’s outlook and discuss its Surgical and Vision Care businesses. Such events are typically accompanied by webcasts and formal announcements. By monitoring this news feed, readers can track key developments affecting Alcon’s product portfolio, strategic direction and presence in the global eye care market.
Horizon Sports & Experiences (HS&E) has announced Shark Beauty™ as the title sponsor for the inaugural Shark Beauty™ Women's Champions Classic, a primetime women's college basketball showcase. The event, scheduled for December 7 at Barclays Center in Brooklyn, will feature the University of Connecticut, University of Iowa, University of Louisville, and University of Tennessee in a doubleheader broadcast on FOX.
This collaboration between HS&E and FOX Sports marks a significant step in elevating women's college basketball. Shark Beauty™ will receive broadcast and digital integrations, sponsorship elements, hospitality, fan engagement activation, and in-arena signage as part of its multiyear partnership. The event aims to provide a national spotlight for women's basketball and introduce Shark Beauty to a wide audience of passionate fans.
Alcon (ALC) reported strong Q2 2024 results with record sales of $2.5 billion, up 3% (6% constant currency). Key highlights include:
- Diluted EPS of $0.45, up 32% (47% cc)
- Core diluted EPS of $0.74, up 7% (15% cc)
- H1 2024 cash from operations of $871 million
- Free cash flow of $667 million, up 253%
Growth was driven by robust demand for innovative products, balanced geographic footprint, and strong execution. Surgical sales increased 3% (6% cc) to $1.4 billion, with strength in international markets. Vision Care sales grew 4% (6% cc) to $1.1 billion, led by contact lenses. The company maintained its 2024 outlook, projecting 7-9% constant currency sales growth and core diluted EPS of $3.00-$3.10.
Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received U.S. FDA 510(k) clearance. These systems are the first innovations from Alcon's Unity portfolio, aimed at transforming surgical procedures in ophthalmology. Alcon plans to gather real-world user feedback in the U.S. before a broad commercialization in 2025. The Unity systems are set to replace Alcon's current leading systems and introduce significant workflow efficiencies. Regulatory submissions will continue globally, with a CE Mark expected in early 2025.
Alcon reported strong first-quarter 2024 financial results, with sales reaching $2.4 billion, a 5% increase (7% constant currency). Diluted EPS rose 43% to $0.50, while core diluted EPS improved by 11% to $0.78. The company saw significant growth in its Surgical and Vision Care segments, particularly in innovative contact lenses, which achieved record sales. Operating income rose to $368 million, with a 15.1% operating margin. Cash from operations jumped to $341 million, with free cash flow at $229 million, a $248 million year-over-year increase. A dividend of CHF 0.24 per share was approved. The company's 2024 outlook remains optimistic, maintaining sales and core EPS guidance.
Alcon Inc. announced the successful approval of all proposed resolutions at its 2024 Annual General Meeting. This includes the approval of a dividend of CHF 0.24 per share, re-election of F. Michael Ball as Chair of the Board of Directors, approval of the Board and Executive Committee compensation, and acceptance of financial reports. Shareholders also re-elected other members of the Board and committees, granted discharge to Board and Executive Committee members, and re-elected auditors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Alcon (ALC)?
What is the market cap of Alcon (ALC)?
